Platelet RNA-Seq Reveals Genes Associated with Carotid Intima-Media Thickness: A Cross-Sectional Study

Zhanfei Tan1, Fan Guo2,3, Jiaming Gao2,3

  • 1Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Insights

This study identified four key platelet genes (ITGA2B, TGFB1, PF4, GP9) associated with atherosclerosis progression. These genes show potential as novel biomarkers for diagnosing and predicting atherosclerosis risk.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Atherosclerosis (AS) risk is linked to platelet characteristics, but their precise role is unclear.
  • Understanding platelet function is crucial for AS pathogenesis and diagnosis.

Purpose of the Study:

  • Identify platelet gene expression differences in patients with and without AS.
  • Discover novel platelet-derived biomarkers for AS diagnosis and risk assessment.

Main Methods:

  • Cross-sectional study comparing AS patients and healthy controls (N).
  • Carotid ultrasound used to measure intima-media thickness (IMT) for AS definition.
  • Platelet RNA sequencing (RNA-seq) performed on extracted plasma platelets.

Main Results:

  • Identified 784 differentially expressed genes in AS patients, including 141 downregulated and 643 upregulated.
  • Gene Ontology analysis revealed significant enrichment in blood coagulation pathways.
  • Weighted correlation network analysis identified four hub genes (ITGA2B, TGFB1, PF4, GP9) correlated with IMT.

Conclusions:

  • Elevated ITGA2B, TGFB1, PF4, and GP9 levels showed moderate correlations with increased IMT.
  • These genes are potential predictive biomarkers for atherosclerosis.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
5.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.8K